Overcoming calcineurin dependence in membranous nephropathy: is rituximab the answer?
Fervenza
Fernando C
FC
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D058846:Antibodies, Monoclonal, Murine-Derived; D065095:Calcineurin Inhibitors; D018450:Disease Progression; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D015433:Glomerulonephritis, Membranous / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D065095:Calcineurin Inhibitors; D004791:Enzyme Inhibitors; D007155:Immunologic Factors; D000069283:Rituximab